Evaluation of Antigen-specific T Cells in Patients With Antisynthetase Syndrome and Interstitial Lung Disease

Launched by CENTRAL HOSPITAL, NANCY, FRANCE · Aug 2, 2023

Keywords

ClinConnect Summary

This clinical trial is investigating a specific type of immune cell in patients with Antisynthetase Syndrome (AS) who also have Interstitial Lung Disease (ILD). AS is a rare condition that affects the muscles and can lead to serious lung problems. The researchers want to understand how certain immune cells, known as Th1 and Th17 cells, relate to the severity of ILD and how patients respond to treatment over six months. By studying these cells, they hope to find better ways to treat patients with AS and ILD.

To participate in this trial, you must be newly diagnosed with AS and have ILD. However, if you have another condition that could cause lung issues, or if you've been on certain medications like corticosteroids in the past three months, you may not be eligible. If you join the study, you can expect to undergo tests that will help researchers learn more about your immune response and how it affects your lung health. This could contribute to future treatments for others facing similar challenges.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient with new diagnosis of AS with ILD
• Exclusion Criteria:
• • Patient with ILD differential diagnosis
• • Corticosteroid treatment, immunosuppresive or immunomodulatory drugs in the past 3 months before diagnosis